drugset
drugset / Trial / NCT00952887

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women

NCT00952887 ↗

Phase 1 Completed 70 enrolled Acceleron Pharma, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to establish safe dose levels of ACE-031 in healthy postmenopausal women following multiple dose administration. This study will also evaluate if ACE-031 has an effect on muscle.

Timeline

Start
2009-08
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject RAMATERCEPT Protein / enzyme biologic — Subcutaneous

Indications

muscular atrophy